UK Markets close in 3 hrs 17 mins
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • FTSE 250

    23,574.62
    +140.55 (+0.60%)
     
  • AIM

    1,236.75
    -10.13 (-0.81%)
     
  • GBP/EUR

    1.1873
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • BTC-GBP

    42,882.66
    +1,942.05 (+4.74%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • DOW

    35,870.95
    -60.10 (-0.17%)
     
  • GOLD FUTURES

    1,861.20
    -0.20 (-0.01%)
     
  • NIKKEI 225

    29,683.09
    +84.43 (+0.29%)
     
  • HANG SENG

    25,319.72
    -330.36 (-1.29%)
     
  • DAX

    16,221.73
    -29.40 (-0.18%)
     
  • CAC 40

    7,141.98
    -14.87 (-0.21%)
     

Global Stromal Vascular Fraction Market to Reach $97.6 Million by 2026

·24-min read

Abstract: Global Stromal Vascular Fraction Market to Reach $97. 6 Million by 2026 . Stromal vascular fraction represents an advanced skin treatment option that is built around stem cell therapy and holds high relevance in the regenerative medicine space.

New York, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stromal Vascular Fraction Industry" - https://www.reportlinker.com/p06043658/?utm_source=GNW
The method involves isolation of cells from adipose tissue of a patient. Obtained through the liposuction process, stromal vascular fraction cells encompass adipose-derived stem cells, endothelial cells, mesenchymal stem cells, leukocytes and tissues containing fat cells. stromal vascular fraction is gaining increasing acceptance across clinical settings for treatment of different chronic conditions. In the recent years, the procedure has witnessed rising significance in diverse areas such as orthopedics, internal medicine, general or plastic surgery and wound healing due to desirable availability, ease of harvest and stable phenotype. Moreover, stromal vascular fraction technique is gaining from several advantages of delivery of these cells through intra-articular injection over surgical implantation, like low cost, less invasiveness and enhanced patient compliance. The global market is slated to receive a significant push from rising number of cosmetic surgeries, increasing incidence of musculoskeletal disorders and growing awareness regarding various merits of stem cell therapy.

Amid the COVID-19 crisis, the global market for Stromal Vascular Fraction estimated at US$75.7 Million in the year 2020, is projected to reach a revised size of US$97.6 Million by 2026, growing at a CAGR of 4.2% over the analysis period. Isolation Products, one of the segments analyzed in the report, is projected to grow at a 4% CAGR to reach US$79.3 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Aspiration Products segment is readjusted to a revised 4.9% CAGR for the next 7-year period. This segment currently accounts for a 16.9% share of the global Stromal Vascular Fraction market. The SVF isolation products segment dominates market share due to rising demand for these products across clinical settings. The rising demand for aesthetic & reconstructive procedures will further boost market prospects.

The U.S. Market is Estimated at $28.2 Million in 2021, While China is Forecast to Reach $7.7 Million by 2026

The Stromal Vascular Fraction market in the U.S. is estimated at US$28.2 Million in the year 2021. The country currently accounts for a 35.89% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$7.7 Million in the year 2026 trailing a CAGR of 5.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4% CAGR while Rest of European market (as defined in the study) will reach US$8.1 Million by the end of the analysis period. North America commands a major share of the market, due to increasing demand for reconstructive and aesthetic therapies. The market growth is facilitated by rising awareness pertaining to the use of stem cell therapy to treat several medical conditions and increasing incident of skeletal muscular disorders, including osteoarthritis. The Asia-Pacific region is rapidly emerging as an appealing market on account of continuous expansion of the private healthcare infrastructure and increasing count of private hospitals across rural areas. Stromal vascular fraction is likely to gain from ongoing R&D projects coupled with increasing development and demand for innovative technologies.

Transfer Products Segment to Reach $3.7 Million by 2026

Transfer devices are expected to present new solutions and extend the application scope of stromal vascular fraction. Increasing establishment of private hospitals across urban and rural areas is likely to further bolster the market demand in the coming years. In the global Transfer Products segment, USA, Canada, Japan, China and Europe will drive the 4.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.3 Million in the year 2020 will reach a projected size of US$3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$384.2 Thousand by the year 2026.
Select Competitors (Total 25 Featured)

  • Cellular Biomedicines Group, Inc.

  • Cytori Therapeutics, Inc.

  • GE Healthcare

  • Genesis Biosystems, Inc.

  • Human Med AG

  • InGeneron, Inc.

  • KYOCERA Corporation

  • Tissue Genesis Inc.




Read the full report: https://www.reportlinker.com/p06043658/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Stem Cells, Application Areas, and the Different Types: A Prelude
Applications of Stem Cells
Types of Stem Cells
Stromal Vascular Fraction: An Introduction
Production Method for SVF
SVF Cell Procedure
SVF Composition, Content, and Source
SVF: Mechanism of Action
SVF: Clinical Applications
Safety and Efficiency of SVF
Clinical Trials and Regulations Related to SVF
Limitations and Scope
Impact of Covid-19 and a Looming Global Recession
COVID-19 Impact on Stromal Vascular Fraction Market
GLOBAL MARKET OVERVIEW
Extensive Therapeutic Scope Set to Stimulate Growth of Global
Stromal Vascular Fraction Market
Soft Tissue Segment Leads the Market
SVF Isolation Products Continue to Make Gains
North America Dominates the Global Market, Asia-Pacific to
Witness Fastest Growth
Lucrative Opportunities & Restraints
Market Restraints
Salient Drivers Offering Growth Impetus to Stromal Vascular
Fraction Market
Extensive Application Scope
Rising Focus on Non-Enzymatic Isolation Techniques
Strong Research Focus on Optimization of Tissue Recovery
Consistent Efforts to Develop Better Cell Therapies
Competition
Players Bet on Product Innovation to Push Footprint in Stromal
Vascular Fraction Market
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Regenerative Medicine: A Promising Application of Stromal
Vascular Fraction
EXHIBIT 1: Global Regenerative Medicine Market Size in US$
Billion for 2019, 2021, 2023 and 2025
EXHIBIT 2: Global Stem Cell & Regenerative Medicine Market by
Product (in %) for the Year 2019
EXHIBIT 3: Global Regenerative Medicines Market by Category:
Breakdown (in %) for Biomaterials, Stem Cell Therapies and
Tissue Engineering for 2019
Increased Prevalence of Musculoskeletal Disorders & Knee
Osteoarthritis Steers Market Expansion
Use of SVF in Osteoarthritis Treatment
Surging Demand for Aesthetic & Reconstructive Therapies
Enhances Market Prospects
EXHIBIT 4: Total Number of Surgical Procedures Performed across
the Globe by Plastic Surgeons (2018)
EXHIBIT 5: Total Number of Surgical Procedures across the Globe
by Region of the Body: 2018
Increasing Awareness about Stem Cell Therapy Augurs Well
Innovative Methods Become Relevant in Optimizing Tissue Recovery
Stromal Vascular Formation Holds Significance for Chronic Diseases
EXHIBIT 6: Fatalities by Heart Conditions: Estimated Percentage
Breakdown for Cardiovascular Disease, Ischemic Heart Disease,
Stroke, and Others
Stromal Vascular Fraction in Diabetic Care
EXHIBIT 7: Rising Diabetes Prevalence Presents Opportunity for
iPSCs Market: Number of Adults (20-79) with Diabetes
(in Millions) by Region for 2017 and 2045
Low Temperature Settings Optimize Vitality of Adipose Tissue-
derived SVFs
SVF Offers Helpful Microenvironment to Regulate ASC Activity
under Specific Clinical Conditions
Swift Influx of Stem Cell Therapies Requires Alternate
Regulatory Pathway Covering Autologous SVF
The Counterview
Contrast with Regulatory Framework Covering HCT/Ps
Aging Demographics Add to the Global Burden of Chronic
Diseases, Presenting Opportunities for Stromal Vascular
Fraction
EXHIBIT 8: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
High Incidence of Neurological Disorders: A Key Market Driver
EXHIBIT 9: Annual Incidence of Adult-Onset Neurologic Disorders
in the US
EXHIBIT 10: Diagnosed Prevalence Cases of Parkinson?s Disease
across Select Countries
Increase in Healthcare Spending Stirs Demand for Stromal
Vascular Fraction
EXHIBIT 11: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Expansion of Private Hospitals in Rural Areas
PIPELINE ANALYSIS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Stromal Vascular
Fraction by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 2: World 7-Year Perspective for Stromal Vascular Fraction
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2021 & 2027

Table 3: World Current & Future Analysis for Isolation Products
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 4: World 7-Year Perspective for Isolation Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 5: World Current & Future Analysis for Aspiration
Products by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 6: World 7-Year Perspective for Aspiration Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 7: World Current & Future Analysis for Transfer Products
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 8: World 7-Year Perspective for Transfer Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 9: World Current & Future Analysis for Soft Tissue by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 10: World 7-Year Perspective for Soft Tissue by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 11: World Current & Future Analysis for Cosmetic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 12: World 7-Year Perspective for Cosmetic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2021 & 2027

Table 13: World Current & Future Analysis for Orthopedic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World 7-Year Perspective for Orthopedic by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2021 & 2027

Table 15: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 16: World 7-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 17: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 18: World 7-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2021 & 2027

Table 19: World Current & Future Analysis for Specialty Clinics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 20: World 7-Year Perspective for Specialty Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 21: World Current & Future Analysis for Stem Cell
Banks/Laboratories by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 22: World 7-Year Perspective for Stem Cell
Banks/Laboratories by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2021 & 2027

Table 23: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 24: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 25: USA Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 26: USA 7-Year Perspective for Stromal Vascular Fraction
by Product Type - Percentage Breakdown of Value Sales for
Isolation Products, Aspiration Products and Transfer Products
for the Years 2021 & 2027

Table 27: USA Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 28: USA 7-Year Perspective for Stromal Vascular Fraction
by Application - Percentage Breakdown of Value Sales for Soft
Tissue, Cosmetic, Orthopedic and Other Applications for the
Years 2021 & 2027

Table 29: USA Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 30: USA 7-Year Perspective for Stromal Vascular Fraction
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Specialty Clinics, Stem Cell Banks/Laboratories and Other
End-Uses for the Years 2021 & 2027

CANADA
Table 31: Canada Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 32: Canada 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 33: Canada Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 34: Canada 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 35: Canada Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 36: Canada 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

JAPAN
Table 37: Japan Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 38: Japan 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 39: Japan Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 40: Japan 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 41: Japan Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 42: Japan 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

CHINA
Table 43: China Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 44: China 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 45: China Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 46: China 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 47: China Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 48: China 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

EUROPE
Table 49: Europe Current & Future Analysis for Stromal Vascular
Fraction by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 50: Europe 7-Year Perspective for Stromal Vascular
Fraction by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2021 & 2027

Table 51: Europe Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 52: Europe 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 53: Europe Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 54: Europe 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 55: Europe Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 56: Europe 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

FRANCE
Table 57: France Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 58: France 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 59: France Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 60: France 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 61: France Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 62: France 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

GERMANY
Table 63: Germany Current & Future Analysis for Stromal
Vascular Fraction by Product Type - Isolation Products,
Aspiration Products and Transfer Products - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 64: Germany 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 65: Germany Current & Future Analysis for Stromal
Vascular Fraction by Application - Soft Tissue, Cosmetic,
Orthopedic and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 66: Germany 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 67: Germany Current & Future Analysis for Stromal
Vascular Fraction by End-Use - Hospitals, Specialty Clinics,
Stem Cell Banks/Laboratories and Other End-Uses - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 68: Germany 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

ITALY
Table 69: Italy Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 70: Italy 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 71: Italy Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 72: Italy 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 73: Italy Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 74: Italy 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

UNITED KINGDOM
Table 75: UK Current & Future Analysis for Stromal Vascular
Fraction by Product Type - Isolation Products, Aspiration
Products and Transfer Products - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 76: UK 7-Year Perspective for Stromal Vascular Fraction
by Product Type - Percentage Breakdown of Value Sales for
Isolation Products, Aspiration Products and Transfer Products
for the Years 2021 & 2027

Table 77: UK Current & Future Analysis for Stromal Vascular
Fraction by Application - Soft Tissue, Cosmetic, Orthopedic and
Other Applications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 78: UK 7-Year Perspective for Stromal Vascular Fraction
by Application - Percentage Breakdown of Value Sales for Soft
Tissue, Cosmetic, Orthopedic and Other Applications for the
Years 2021 & 2027

Table 79: UK Current & Future Analysis for Stromal Vascular
Fraction by End-Use - Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: UK 7-Year Perspective for Stromal Vascular Fraction
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Specialty Clinics, Stem Cell Banks/Laboratories and Other
End-Uses for the Years 2021 & 2027

REST OF EUROPE
Table 81: Rest of Europe Current & Future Analysis for Stromal
Vascular Fraction by Product Type - Isolation Products,
Aspiration Products and Transfer Products - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 82: Rest of Europe 7-Year Perspective for Stromal
Vascular Fraction by Product Type - Percentage Breakdown of
Value Sales for Isolation Products, Aspiration Products and
Transfer Products for the Years 2021 & 2027

Table 83: Rest of Europe Current & Future Analysis for Stromal
Vascular Fraction by Application - Soft Tissue, Cosmetic,
Orthopedic and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 84: Rest of Europe 7-Year Perspective for Stromal
Vascular Fraction by Application - Percentage Breakdown of
Value Sales for Soft Tissue, Cosmetic, Orthopedic and Other
Applications for the Years 2021 & 2027

Table 85: Rest of Europe Current & Future Analysis for Stromal
Vascular Fraction by End-Use - Hospitals, Specialty Clinics,
Stem Cell Banks/Laboratories and Other End-Uses - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 86: Rest of Europe 7-Year Perspective for Stromal
Vascular Fraction by End-Use - Percentage Breakdown of Value
Sales for Hospitals, Specialty Clinics, Stem Cell
Banks/Laboratories and Other End-Uses for the Years 2021 & 2027

ASIA-PACIFIC
Table 87: Asia-Pacific Current & Future Analysis for Stromal
Vascular Fraction by Product Type - Isolation Products,
Aspiration Products and Transfer Products - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 88: Asia-Pacific 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 89: Asia-Pacific Current & Future Analysis for Stromal
Vascular Fraction by Application - Soft Tissue, Cosmetic,
Orthopedic and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 90: Asia-Pacific 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 91: Asia-Pacific Current & Future Analysis for Stromal
Vascular Fraction by End-Use - Hospitals, Specialty Clinics,
Stem Cell Banks/Laboratories and Other End-Uses - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 92: Asia-Pacific 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

REST OF WORLD
Table 93: Rest of World Current & Future Analysis for Stromal
Vascular Fraction by Product Type - Isolation Products,
Aspiration Products and Transfer Products - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 94: Rest of World 7-Year Perspective for Stromal Vascular
Fraction by Product Type - Percentage Breakdown of Value Sales
for Isolation Products, Aspiration Products and Transfer
Products for the Years 2021 & 2027

Table 95: Rest of World Current & Future Analysis for Stromal
Vascular Fraction by Application - Soft Tissue, Cosmetic,
Orthopedic and Other Applications - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 96: Rest of World 7-Year Perspective for Stromal Vascular
Fraction by Application - Percentage Breakdown of Value Sales
for Soft Tissue, Cosmetic, Orthopedic and Other Applications
for the Years 2021 & 2027

Table 97: Rest of World Current & Future Analysis for Stromal
Vascular Fraction by End-Use - Hospitals, Specialty Clinics,
Stem Cell Banks/Laboratories and Other End-Uses - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 98: Rest of World 7-Year Perspective for Stromal Vascular
Fraction by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories and
Other End-Uses for the Years 2021 & 2027

IV. COMPETITION
Total Companies Profiled: 25
Read the full report: https://www.reportlinker.com/p06043658/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting